Q-omics provides the consensus-scored MYO9A profile across patient tissues and cancer cell-line models. MYO9A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYO9A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MYO9A RNA expression shows 22,023 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where MYO9A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO9A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO9A survival associations across molecular data types. MYO9A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (10) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO9A RNA expression–survival associations across cancer types. High MYO9A expression shows unfavorable associations in ACC, BLCA and UVM, but favorable associations in KIRC, ESCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYO9A RNA expression.
This table summarizes MYO9A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MYO9A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO9A shows lower tumor expression in THCA, KICH, LUAD, UCEC and LUSC and higher tumor expression in HNSC. The THCA box plot shows higher MYO9A RNA expression in normal versus tumor tissue (log2 FC = −1.119, t-test p < 0.001).
This table shows molecular features associated with MYO9A in patient tissues and cancer cell lines. In patient samples, MYO9A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO9A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
